WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317901
CAS#: 61718-82-9 (maleate)
Description: Fluvoxamine is a medication which functions as a selective serotonin reuptake inhibitor (SSRI) and σ1 receptor agonist. Fluvoxamine is used primarily for the treatment of obsessive-compulsive disorder (OCD), and is also used to treat major depressive disorder (MDD), and anxiety disorders such as panic disorder and post-traumatic stress disorder (PTSD).
Hodoodo Cat#: H317901
Name: Fluvoxamine maleate
CAS#: 61718-82-9 (maleate)
Chemical Formula: C19H25F3N2O6
Exact Mass: 0.00
Molecular Weight: 434.412
Elemental Analysis: C, 52.53; H, 5.80; F, 13.12; N, 6.45; O, 22.10
Related CAS #: 61718-82-9 (maleate) 54739-18-3 (free base)
Synonym: Fluvoxamine maleate, Faverin, Fevarin, Floxyfral, Luvox
IUPAC/Chemical Name: 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine maleate
InChi Key: LFMYNZPAVPMEGP-PIDGMYBPSA-N
InChi Code: InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
SMILES Code: FC(C1=CC=C(/C(CCCCOC)=N/OCCN)C=C1)(F)F.O=C(O)/C=C\C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Fluvoxamine maleate (DU-23000 maleate) is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. |
| In vitro activity: | On the other hand, when cells were pre-treated with Flv (fluvoxamine) followed by co-treatment with Px/Flv for 24 h, the induction of CHOP, cleaved caspase 4 and cleaved caspase 3 were alleviated compared to the Flv-untreated cells (Fig. 2a–c, p<0.05, p<0.05, and p<0.01, respectively). Reference: Biochem Biophys Rep. 2015 Dec; 4: 202–206. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668922/ |
| In vivo activity: | As illustrated in Figure 5b, fluvoxamine at doses of 25 and 50 mg/kg, considerably decreased the expression of iNOS (P=0.02, P=0.01) in carrageenan induced paw edema in rats. COX-2 expression was significantly reduced by fluvoxamine at a dose of 50 mg/kg (P=0.04). Reference: Iran J Basic Med Sci. 2016 Sep; 19(9): 977–984. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080428/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 72.3 | 166.50 | |
| DMF | 30.0 | 69.06 | |
| Ethanol | 56.0 | 128.91 | |
| PBS (pH 7.2) | 5.0 | 11.51 | |
| Water | 12.2 | 28.01 |
The following data is based on the product molecular weight 434.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, Ghanbari A. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017 Jul 7;7(1):4923. doi: 10.1038/s41598-017-04968-z. PMID: 28687730; PMCID: PMC5501834. 2. Tanimukai H, Kudo T. Fluvoxamine alleviates paclitaxel-induced neurotoxicity. Biochem Biophys Rep. 2015 Sep 25;4:202-206. doi: 10.1016/j.bbrep.2015.09.014. PMID: 29124205; PMCID: PMC5668922. |
| In vitro protocol: | 1. Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, Ghanbari A. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017 Jul 7;7(1):4923. doi: 10.1038/s41598-017-04968-z. PMID: 28687730; PMCID: PMC5501834. 2. Tanimukai H, Kudo T. Fluvoxamine alleviates paclitaxel-induced neurotoxicity. Biochem Biophys Rep. 2015 Sep 25;4:202-206. doi: 10.1016/j.bbrep.2015.09.014. PMID: 29124205; PMCID: PMC5668922. |
| In vivo protocol: | 1. Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci. 2016 Sep;19(9):977-984. PMID: 27803785; PMCID: PMC5080428. 2. Hayashi K, Michiue H, Yamada H, Takata K, Nakayama H, Wei FY, Fujimura A, Tazawa H, Asai A, Ogo N, Miyachi H, Nishiki T, Tomizawa K, Takei K, Matsui H. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Sci Rep. 2016 Mar 18;6:23372. doi: 10.1038/srep23372. PMID: 26988603; PMCID: PMC4796892. |
1: Altamura AC, Caldiroli A, Buoli M. Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):649-60. doi: 10.1517/17425255.2015.1021331. Epub 2015 Mar 1. Review. PubMed PMID: 25728382.
2: Wigard ME, van Gool AR, Schulte PF. [Addition of fluvoxamine to clozapine: theory and practice]. Tijdschr Psychiatr. 2013;55(2):113-21. Review. Dutch. PubMed PMID: 23408363.
3: Tagashira H, Fukunaga K. [Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist]. Yakugaku Zasshi. 2012;132(2):167-72. Review. Japanese. PubMed PMID: 22293694.
4: Higuchi H. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Apr;30(2):71-6. Review. Japanese. PubMed PMID: 20491280.
5: Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010 Apr;25(3):193-200. doi: 10.1002/hup.1106. Review. PubMed PMID: 20373470.
6: Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114. doi: 10.1002/14651858.CD006114.pub2. Review. PubMed PMID: 20238342; PubMed Central PMCID: PMC4171125.
7: Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord Drug Targets. 2009 Dec;8(6):470-4. Review. PubMed PMID: 19702566.
8: Omori IM, Watanabe N, Nakagawa A, Akechi T, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. J Psychopharmacol. 2009 Jul;23(5):539-50. doi: 10.1177/0269881108089876. Epub 2008 Jun 18. Review. PubMed PMID: 18562407.
9: Owen RT. Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. Drugs Today (Barc). 2008 Dec;44(12):887-93. doi: 10.1358/dot.2008.44.12.1299291. Review. PubMed PMID: 19198698.
10: Buhagiar K, Cassar J. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature]. Turk Psikiyatri Derg. 2007 Summer;18(2):179-83. Review. Turkish. PubMed PMID: 17566884.
11: Niwa T, Honda S, Shirakawa K, Imamura Y, Osaki S, Takagi A. [Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor]. Nihon Yakurigaku Zasshi. 2006 Aug;128(2):93-103. Review. Japanese. PubMed PMID: 16943644.
12: Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006 Apr;60(4):482-91. Review. PubMed PMID: 16620364; PubMed Central PMCID: PMC1448696.
13: Mitcheson JS. Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine. Br J Pharmacol. 2003 Jul;139(5):883-4. Review. PubMed PMID: 12839860; PubMed Central PMCID: PMC1573930.
14: Cheer SM, Figgitt DP. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. CNS Drugs. 2002;16(2):139-44. Review. PubMed PMID: 11825104.
15: Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev. 2001 Fall;7(3):283-304. Review. PubMed PMID: 11607044.
16: Molenberghs G, Goetghebeur EJ, Lipsitz SR, Kenward MG, Lesaffre E, Michiels B. Missing data perspectives of the fluvoxamine data set: a review. Stat Med. 1999 Sep 15-30;18(17-18):2449-64. Review. PubMed PMID: 10474152.
17: Montejo-González AL, Llorca G, Izquierdo JA, Ledesma A, Bousoño M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997 Fall;23(3):176-94. Review. PubMed PMID: 9292833.
18: Ninan PT. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine. J Clin Psychiatry. 1997;58 Suppl 5:24-31. Review. PubMed PMID: 9184624.
19: DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry. 1997;58 Suppl 5:7-14. Review. PubMed PMID: 9184622.
20: van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. Review. PubMed PMID: 8846617.
